U.S. Markets closed
  • S&P Futures

    4,250.00
    +4.25 (+0.10%)
     
  • Dow Futures

    34,482.00
    +20.00 (+0.06%)
     
  • Nasdaq Futures

    14,019.00
    +24.75 (+0.18%)
     
  • Russell 2000 Futures

    2,332.70
    +2.20 (+0.09%)
     
  • Crude Oil

    70.74
    -0.17 (-0.24%)
     
  • Gold

    1,878.70
    -0.90 (-0.05%)
     
  • Silver

    28.08
    -0.07 (-0.25%)
     
  • EUR/USD

    1.2111
    -0.0066 (-0.5450%)
     
  • 10-Yr Bond

    1.4620
    +0.0030 (+0.21%)
     
  • Vix

    15.65
    -0.45 (-2.80%)
     
  • GBP/USD

    1.4112
    -0.0064 (-0.4516%)
     
  • USD/JPY

    109.7120
    +0.3640 (+0.3329%)
     
  • BTC-USD

    39,017.46
    +3,053.66 (+8.49%)
     
  • CMC Crypto 200

    924.19
    -17.62 (-1.87%)
     
  • FTSE 100

    7,134.06
    +45.88 (+0.65%)
     
  • Nikkei 225

    28,948.73
    -9.87 (-0.03%)
     

Analyst Forecasts Just Became More Bearish On Viela Bio, Inc. (NASDAQ:VIE)

·3 min read

Today is shaping up negative for Viela Bio, Inc. (NASDAQ:VIE) shareholders, with the analysts delivering a substantial negative revision to this year's forecasts. This report focused on revenue estimates, and it looks as though the consensus view of the business has become substantially more conservative. Shares are up 9.9% to US$33.29 in the past week. Investors could be forgiven for changing their mind on the business following the downgrade; but it's not clear if the revised forecasts will lead to selling activity.

After the downgrade, the consensus from Viela Bio's seven analysts is for revenues of US$12m in 2020, which would reflect a concerning 59% decline in sales compared to the last year of performance. Losses are expected to be contained, narrowing 17% from last year to US$3.06. Yet prior to the latest estimates, the analysts had been forecasting revenues of US$14m and losses of US$3.02 per share in 2020. So there's been quite a change-up of views after the recent consensus updates, with the analysts making a serious cut to their revenue forecasts while also making no real change to the loss per share numbers.

View our latest analysis for Viela Bio

earnings-and-revenue-growth
earnings-and-revenue-growth

There was no real change to the consensus price target of US$60.50, suggesting that the revisions to revenue estimates are not expected to have a long-term impact on Viela Bio's valuation. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. The most optimistic Viela Bio analyst has a price target of US$75.00 per share, while the most pessimistic values it at US$48.00. There are definitely some different views on the stock, but the range of estimates is not wide enough as to imply that the situation is unforecastable, in our view.

One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. These estimates imply that sales are expected to slow, with a forecast revenue decline of 59%, a significant reduction from annual growth of 50% over the last year. By contrast, our data suggests that other companies (with analyst coverage) in the same industry are forecast to see their revenue grow 21% annually for the foreseeable future. It's pretty clear that Viela Bio's revenues are expected to perform substantially worse than the wider industry.

The Bottom Line

Regrettably, they also downgraded their revenue estimates, and the latest forecasts imply the business will grow sales slower than the wider market. Overall, given the drastic downgrade to this year's forecasts, we'd be feeling a little more wary of Viela Bio going forwards.

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. At Simply Wall St, we have a full range of analyst estimates for Viela Bio going out to 2024, and you can see them free on our platform here.

Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies that insiders are buying.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.